Treatment planning with a tablet, calendar, and notes.

Private, no account, nothing stored on a server

My biologic-start checklist

Select whatever applies to you and take a short summary to your next appointment. Nothing produces a clearance and nothing is assessed.

My biologic-start checklist

Nothing is preselected, nothing is required, and every section can be skipped. Even with no selections at all, you already get questions for the conversation.

Your selections are never assessed. There is no “ready” and no “not ready” — the checklist only records what you want to raise.

Step 1 / 9

Your medicine

Which biologic are you preparing to start?

Your medicine

Step 2 / 9

Current health

Select only what applies to you. Selecting something does not mean you cannot use the medicine — it only adds a question to your summary.

Current health

None of these apply? Then simply skip this section.

Step 3 / 9

Tuberculosis screening

Has TB screening already been discussed or completed?

Tuberculosis screening
Have you ever been treated for TB, had a positive TB test, or had close contact with someone with active TB?

Step 4 / 9

Vaccinations

Has your vaccination status already been reviewed?

Vaccinations

Live vaccines should not be given while on secukinumab; non-live vaccines can be given.

Certain live vaccines should not be given during bimekizumab treatment.

Step 5 / 9

Specific to your medicine

Specific to adalimumab

Adalimumab is a TNF-alpha inhibitor. Current EMA product information requires evaluation for both active and latent tuberculosis before treatment starts, because an existing — even silent — infection can reactivate under this drug class.

Have you ever been told you have moderate or severe heart failure?
Have you previously had hepatitis B, or been told a hepatitis B test was positive?

Specific to secukinumab

Current secukinumab product information warns about new or worsening inflammatory bowel disease and advises against giving live vaccines at the same time.

Do you have Crohn's disease, ulcerative colitis, or ongoing unexplained bowel symptoms?

Specific to bimekizumab

Current bimekizumab product information asks patients to discuss previous inflammatory bowel disease, recurrent infection, previous tuberculosis and planned vaccination. Oral candidiasis (thrush) is among the more common side effects.

Do you have Crohn's disease, ulcerative colitis, or ongoing unexplained bowel symptoms?
Do you frequently develop fungal infections, such as oral or genital thrush?

Specific to your medicine

Your medicine may have its own requirements for screening, vaccination and medical history. Ask explicitly which of these apply specifically to the biologic you have been prescribed.

Select your medicine in step 1 first to see the points that apply to it.

Step 6 / 9

Medicines and practical preparation

Is your current medication list ready?

Medicines and practical preparation
What is already clear about using the medicine? Select whatever is still unclear.

Step 7 / 9

Your baseline

How is your HS right now, just before the first dose? Everything here is optional.

Currently affected body areas
Current pain (0–10)
Current drainage
Impact on daily life

None of these apply? Then simply skip this section.

Step 8 / 9

Your treatment priority

What matters most to you about this treatment?

Your treatment priority

When will the effect be reviewed?

Has a date or timeframe already been agreed to decide whether treatment is working well enough?

When will the effect be reviewed?

Step 9 / 9

Your biologic-start checklist

The checklist is built only from what you selected. You can copy it, print it or save it as a PDF.

Use this checklist

There is deliberately no share link: nothing you select here is ever given an address on the internet.

Delete my answers

Back to the overview

Evidence and editorial review

Last editorially reviewed: · Next review:

Drug-specific details checked:

The statements about TB screening, active infection and vaccination rest on current EMA product information for Humira, Cosentyx and Bimzelx, and on Robert Koch Institute guidance on vaccination during immunosuppression.

Product information can change. The drug-specific content is therefore reviewed every six months — faster than the rest of the text on these pages.

Nothing on these pages replaces the individual assessment made by your treating clinician, and no selection in the checklist produces a recommendation to start, delay or skip a treatment.

Editorial policy and review process

My HS Home Your appointment questions, saved tools and more in one place — no account needed. Treatment Options for Acne Inversa The treatment classes at a glance, with biologics as one of several layers. Prepare a treatment conversation A neutral tool to record what matters to you and build questions for the appointment. My HS care team Who may be involved in HS care and how appointments can be coordinated. Track your symptoms A baseline here can also be continued as ongoing tracking. Find an HS specialist Dermatology practices with HS experience in Germany. When to get medical help The page to fall back on whenever it is unclear whether something needs looking at soon.

Sources

  1. Humira (adalimumab) — European public assessment report European Medicines Agency (EMA) · Checked: 2026-08-25
  2. Humira — current product information European Medicines Agency (EMA) · Checked: 2026-08-25
  3. Cosentyx (secukinumab) — European public assessment report European Medicines Agency (EMA) · Checked: 2026-08-25
  4. Cosentyx — current product information European Medicines Agency (EMA) · Checked: 2026-08-25
  5. Bimzelx (bimekizumab) — European public assessment report European Medicines Agency (EMA) · Checked: 2026-08-25
  6. Bimzelx — current product information European Medicines Agency (EMA) · Checked: 2026-08-25
  7. Contraindications and vaccination under immunosuppression — frequently asked questions Robert Koch Institute (RKI), Germany · Checked: 2026-08-25
  8. Recommendations for tuberculosis screening before biologic therapy in special patient populations with hidradenitis suppurativa PubMed, US National Library of Medicine · Checked: 2026-08-25
  9. Hidradenitis suppurativa: Diagnosis and treatment American Academy of Dermatology (AAD) · Checked: 2026-08-25